There were several modifications in the paper. They are shown as follows.

Page 1, Abstract: the sentence in the abstract "Dose limiting toxicities (DLT) were grade (G) 3 nonhematologic and G4 hematologic events" should read "... and G4 hematologic events *related to platelets and granulocytes only*."

"GEM 1380 mg/m^2^ and mistletoe 250 mg combined were the MTD" should read "GEM 1300 mg/m^2^ and mistletoe 250 mg combined were the MTD."

Page 2, Introduction: "While ML antibodies were absent in patients without adverse effects,..." should read "While ML *antibodies type IgE* were absent in patients ...."

Page 2, Materials and Methods: "A whole plant mistletoe extract (HELIXOR Apis (A), growing on fir trees)" should read "A whole plant mistletoe extract (Helixor A (*Abietis*), growing on fir trees),"

Page 2, Materials and Methods: "Helixor, GmbH, Rosenfeld" should read "Helixor Heilmittel *GmbH & Co. KG,* Rosenfeld."

Page 3, Study Design and Outcomes: the sentence "... was administered with gemcitabine in 20% dose increments per dose level (900, 1080, 1380, and 1560 mg/m^2^...)" should read "... (900, 1080, 1300, and 1560 mg/m^2^...)."

Page 4, Results: Maximum Tolerated Dose and Dose Limiting Toxicities. The last sentence in this paragraph should read as follows: Thus, we achieved the MTD at dose level 8 (*gemcitabine*1300 mg/m^2^ and mistletoe 250 mg).

Paragraph 3.4. "Three study participants experienced individual DLTs at dose level 9 (gemcitabine 1560 mg/m^2^ with 250 mg daily of mistletoe). These included grade 3 cellulitis at the mistletoe injection site, grade 4 acute renal failure, and grade 4 neutropenia" should read "... and grade 4 *thrombocytopenia.*"

Page 8, Discussion: the sentence "The MTD for the gemcitabine/mistletoe combination in this study was gemcitabine 1380 mg/m^2^..." should read "The MTD for the gemcitabine/mistletoe combination in this study was gemcitabine 1300 mg/m^2^...."

Page 8, [Table 4](#tab1){ref-type="table"}: Dose limiting toxicities by dose level. "Level/dosage 8 (250 mg/day mistletoe; 1380 mg/m^2^ GEM on day 1/8 of 3-week cycle)" should read "Level/dosage 8 (250 mg/day mistletoe; 1300 mg/m^2^ GEM on day 1/8 of 3-week cycle)."

Page 9, Discussion: the sentence "None of the study patients developed febrile neutropenia even at the highest gemcitabine dose of 1650 mg/m^2^" should read "None of the study patients developed febrile neutropenia even at the highest gemcitabine dose of 1560 mg/m^2^."

Page 9, Conclusion: The sentence "the MTD was gemcitabine 1380 mg/m^2^ weekly ..." should read "the MTD was gemcitabine 1300 mg/m^2^ weekly ...."

Page 10, Acknowledgments: the second sentence should read: They greatly appreciate ... the support of Drs*. Dietrich* Schlodder and *Jörg* Schierholz.

The sentence "... as well as Sabine Rieger from Helixor GmbH" should read "... as well as Sabine Rieger from *Helixor Heilmittel GmbH & Co. KG*."

The sentence "Mistletoe extract (Helixor A) was provided by Helixor GmbH, Rosenfeld,..." should read "Mistletoe extract (Helixor A) was provided by *Helixor Heilmittel GmbH & Co. KG, Rosenfeld,* ...."

###### 

Dose limiting toxicities by dose level.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stage I (fixed GEM dose of 750 mg/m^2^)                         Stage II (fixed mistletoe dose, established in stage 1)                                                                                                                                                                              
  --------------------------------------------------------------- --------------------------------------------------------- ------ ------------------------------------------------------------------------- --- ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  (1)\                                                            3                                                         None   (6)\                                                                      7   Grade 4 neutropenia                                                                   Dose reduced; enrolled 3 more patients at this dose level.
  (escalating daily mistletoe injections, reaching: 20 mg/day)                                                                     (250 mg/day mistletoe; **900** mg/m^2^ GEM on day 1/8 of 3-week cycle)                                                                                              

  (2)\                                                            3                                                         None   (7)\                                                                      7   Grade 4 thrombocytopenia                                                              Dose reduced; enrolled 3 more patients at this dose level.
  (escalating daily mistletoe injections, reaching: 50 mg/day)                                                                     (250 mg/day mistletoe; **1080** mg/m^2^ GEM on day 1/8 of 3-week cycle)                                                                                             

  (3)\                                                            3                                                         None   (8)\* \                                                                   6   None                                                                                  N/A
  (escalating daily mistletoe injections, reaching: 100 mg/day)                                                                    (250 mg/day mistletoe; **1300** mg/m^2^ GEM on day 1/8 of 3-week cycle)                                                                                             

  (4)\                                                            6                                                         None   (9)\                                                                      4   Grade 3 cellulitis^a^; grade 4 acute renal failure^b^; grade 4: thrombocytopenia^c^   ^a^mistletoe therapy withheld; patient rechallenged and developed hypersensitivity reaction. Mistletoe discontinued; ^b^Pt. treated for renal failure and subsequently withdrawn from study; ^c^Pt. hospitalized d/t other AE; *Maximum tolerated dose reached per protocol.*
  (escalating daily mistletoe injections, reaching: 200 mg/day)                                                                    (250 mg/day mistletoe; **1560** mg/m^2^ GEM on day 1/8 of 3-week cycle)                                                                                             

  (5)\                                                            5                                                         None                                                                                                                                                                        
  (escalating daily mistletoe injections, reaching: 250 mg/day)                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Per study protocol, this level represents the maximum tolerated dose, as 3 DLT\'s were observed in the subsequent dose level.
